A Phase 1, Open-Label, Fixed-Sequence Study to Evaluate the Effect of Itraconazole and Cyclosporine on the Single-Dose Pharmacokinetics of Danuglipron in Healthy Adult Participants

The purpose of this study is to see how single dose of cyclosporine and multiple doses of itraconazole affect the level of the study medicine danuglipron in the blood of healthy adult participants. The information from this study may inform how danuglipron will be used in the future with medicines like cyclosporine and itraconazole.

Start Date16 Dec 2024

Sponsor / Collaborator

Pfizer Inc.

NCT06567327 / RecruitingPhase 1

A Two-Part Phase 1, Open-Label, Fixed-Sequence Study to Evaluate the Multiple Dose Pharmacokinetics of Danuglipron Following Oral Administration and The Effects of Steady-State Danuglipron on the Pharmacokinetics of Single Oral Dose of Atorvastatin and Rosuvastatin in Otherwise Healthy Adult Participants With Overweight or Obesity

The purpose of this study is to learn the following about the study medicine, danuglipron, after multiple days of dosing in healthy adults who are overweight or obese:
* how the study medicine, danuglipron, is taken up into the blood
* if the study medicine, danuglipron, changes how the body processes other study medicines (Atorvastatin and Rosuvastatin)
* about the safety and tolerability of danuglipron
The study will take place in 2 Cohorts (groups). The total number of weeks of the study is about 23 (about 6 months) for Cohort 1 and 22 weeks (about 5.5 months) for Cohort 2, 21 weeks (about 5 months) for Cohort 3 and 20 weeks (about 5 months) for Cohort 4.

Start Date28 Aug 2024

Sponsor / Collaborator

Pfizer Inc.

NCT06568731 / Active, not recruitingPhase 1

A PHASE 1, OPEN- LABEL STUDY TO EVALUATE THE MULTIPLE DOSE PHARMACOKINETICS OF DANUGLIPRON FOLLOWING ORAL ADMINISTRATION IN OTHERWISE HEALTHY ADULT PARTICIPANTS WITH OVERWEIGHT OR OBESITY

Start Date23 Aug 2024

Sponsor / Collaborator

Pfizer Inc.

100 Clinical Results associated with Danuglipron

100 Translational Medicine associated with Danuglipron

100 Patents (Medical) associated with Danuglipron

Literatures (Medical) associated with Danuglipron

01 Nov 2024·TOXICOLOGY AND APPLIED PHARMACOLOGY

Toxicology profile of a novel GLP-1 receptor biased agonist-SAL0112 in nonhuman primates

Article

Author: Sun, Jingchao ; Shen, Xiaolei ; Xiao, Ying ; Hu, Xuefeng ; Luo, Binbin ; Zhang, Hongmei ; Huang, Jing ; Ren, Zhiqiang ; Jiang, Rongzhi ; Chen, Shu

Oral small-molecule GLP-1 receptor biased agonists exhibit promising treatment efficacy of type 2 diabetes and obesity. SAL0112 is a novel compound that has demonstrated remarkable efficacy in preclinical animal models. Herein, both in vitro and in vivo preclinical toxicity investigations were conducted to explore the safety profile of SAL0112. The HTRF assay and TR-FRET assay were utilized for cAMP detection. Patch clamp assay was employed for hERG potassium ion channel determination. Cynomolgus monkeys were used in a cardiovascular safety pharmacology study and a 13-week repeated dose toxicity study. The telemetry system was employed to detect cardiovascular indicators such as ECG, HR, and BP. During the repeated dose toxicity study, body weight, food intake, hematology, coagulation function test, serum biochemistry tests, and urine analysis were measured. Macroscopic and microscopic observations were conducted at the end of the study. TK studies were conducted on Day 1 and Day 91. SAL0112 exhibited a high degree of potency in activating the monkey GLP-1 receptor whereas had no effect on the rodent GLP-1 receptor. In contrast to Danuglipron, which demonstrated high potency on hERG with an IC₅₀ value of 6.9 μM, the IC₅₀ of SAL0112 on hERG was greater than 100 μM. Compared to the Vehicle Control group, no significant changes in cardiovascular indicators were observed in the cardiovascular safety pharmacology study after a single dose of SAL0112 up to 250 mg/kg (P > 0.05). A repeated dose toxicity study revealed moderate anorexigenic effects and a reduction in body weight, effects that were found to be reversible and not associated with any pathological changes. The NOAEL of SAL0112 is 150 mg/kg, providing an approximate safety margin of threefold. SAL0112 demonstrated a favorable safety profile in cynomolgus monkeys, with a substantial therapeutic window that supports the progression of this compound into clinical studies.

12 Sep 2024·JOURNAL OF MEDICINAL CHEMISTRY

Design and Evaluation of 3-Phenyloxetane Derivative Agonists of the Glucagon-Like Peptide-1 Receptor

Article

Author: Liu, Dongzhou ; Cai, Cancan ; Yang, Yacheng ; Zhang, Zhiping ; Yang, Xu ; Wang, Zhiyong ; Zhang, Yuchen ; Pan, Hao ; Zheng, Haowen ; Chen, Tingni ; Zhang, Xiaohua ; Zhang, Zhimin ; Wang, Zhe ; Jiang, Chunhua ; Guo, Liubin

Various small molecule GLP1R agonists have been developed and tested for treating type 2 diabetes (T2DM) and obesity. However, many of these new compounds have drawbacks, such as potential hERG inhibition, lower activity compared to natural GLP-1, limited oral bioavailability in cynomolgus monkeys, and short duration of action. Recently, a new category of 3-phenyloxetane derivative GLP1R agonists with enhanced hERG inhibition has been discovered. Using an AIDD/CADD method, compound 14 (DD202-114) was identified as a potent and selective GLP1R agonist, which was chosen as a preclinical candidate (PCC). Compound 14 demonstrates full agonistic efficacy in promoting cAMP accumulation and possesses favorable drug-like characteristics compared to the clinical drug candidate Danuglipron. Additionally, in hGLP-1R knock-in mice, compound 14 displayed a sustained pharmacological effect, effectively reducing blood glucose levels and food intake. These findings suggest that compound 14 holds promise as a future treatment option for T2DM and obesity, offering improved properties.

01 Aug 2024·BIOMEDICINE & PHARMACOTHERAPY

Pharmacodynamic and pharmacokinetic profiles of a novel GLP-1 receptor biased agonist-SAL0112

Article

Author: Jin, Qian ; Sun, Jingchao ; Xing, Wei ; Xiao, Ying ; Hu, Xuefeng ; Lobie, Peter E ; Jiang, Wenjuan ; Liu, Zhaojun ; Li, Hongchao ; Ren, Peng ; Zhang, Hongmei

BACKGROUND AND PURPOSE:

GLP-1 receptor agonists are clinically utilized for type 2 diabetes and obesity. In vitro and in vivo preclinical studies were performed to assess the druggability of a novel small molecule GLP-1 receptor biased agonist SAL0112.

EXPERIMENTAL APPROACH:

The HTRF assay, FLIPR assay, TR-FRET assay, and PathHunter assay were utilized for in vitro studies. Liver transporter tests were conducted using the HEK293-OATP1B1 and HEK293-OATP1B3 cell lines. In vitro stability assessments of various species and in vivo PK studies in rodents were performed. A model of type 2 diabetes and obesity induced by a high-energy diet in transgenic C57BL/6 mice expressing the human GLP-1 receptor gene was conducted.

PRINCIPAL RESULTS:

SAL0112 demonstrated high potency and selectivity in activating the Gαs pathway of the GLP-1 receptor, with no observed desensitization. SAL0112 demonstrated greater stability in human and rat liver microsomes compared to Danuglipron. In vivo PK studies revealed higher absorption of SAL0112 in rats. SAL0112 displayed a significantly lower potential for DDI on liver transporters compared to Danuglipron. SAL0112 led to significant reductions in body weight (P<0.001), blood glucose levels in OGTT (P<0.001), HbA_1c (P<0.05) and improved insulin resistance (P<0.01). Notably, it increased peripheral adipocyte density and resolved hepatic steatosis. The efficacy of SAL0112 was found to be comparable to that of Danuglipron and Liraglutide.

CONCLUSION:

SAL0112 demonstrated potent and selective GLP-1 receptor biased agonism, effectively alleviating signs of type 2 diabetes in a mouse model. These promising findings pave the way for the advancement of SAL0112 into clinical trials.

News (Medical) associated with Danuglipron

20 Nov 2024

·endpts.com

Pfizer partners with two more Flagship biotechs on obesity, cancer

Pfizer is enlisting another Flagship startup to help it create new obesity medicines. After June’s ProFound Therapeutics tie-up , Pfizer will work with the incubator’s Ampersand Biomedicines in the hunt for new biologics for obesity. The New York pharmaceutical company is also tapping into Flagship-founded Montai Therapeutics to find new small molecules for potentially treating lung cancer, the companies said Wednesday morning. The two pacts are part of Pfizer’s broader alliance with the Cambridge, MA-based Flagship, which recently reeled in about $3.6 billion in new funds as pharma partnerships become a “ bigger and bigger deal .” Pfizer has had an uneven few years in obesity, particularly with its danuglipron program . Last month, it revealed more details about its other early-stage bets: a GIP antagonist and a once-daily oral GLP-1. Ampersand hopes to help Pfizer create obesity treatments that go to a specific site in the body, rather than hitting healthy tissues or cells, so as to avoid side effects — like muscle loss and gastrointestinal concerns — and to make the drugs more potent. The startup, which emerged with $50 million in March 2023, uses computational methods to find “addresses” for drugs to go to and then creates an “actuator” to carry out the therapeutic function, Flagship general partner Avak Kahvejian told Endpoints News last year. In January, it bought antibody discovery tech startup AbCheck, an Affimed subsidiary, for $6 million. “We have addresses in virtually every tissue in the body, so you could think about virtually any disease,” CEO Jason Gardner said in an interview. Ampersand will likely make multiple other industry collaborations, he said, and it could form more tie-ups around obesity. It’s early days with the Pfizer partnership, and Gardner declined to disclose the specific pathway tissue that they’re looking at. Flagship’s work in obesity has also attracted the attention of Novo Nordisk. Its companies Metaphore Biotechnologies and Omega Therapeutics have both formed partnerships with the Danish drugmaker. In cancer, Pfizer’s new partnership with Montai will look at mechanisms that lead to lung cancer cell growth and find new small molecules that can potentially be turned into therapies. Pfizer has made oncology a core focus following its $43 billion Seagen acquisition last year. Montai emerged with $50 million in December 2022 and a high-profile CEO, Margo Georgiadis, who previously led Google’s Americas division and steered Ancestry.com to a nearly $5 billion exit to Blackstone. The startup scours through molecules already consumed by humans via foods, supplements and herbal medicines. Its computational tools have brought together nearly 200 million so-called “Anthromolecules” and their derivatives, Georgiadis said. The company’s name means “climbing mountains with AI,” she said. Georgiadis said in an interview that the company is trying to “create the first machine learning that enables us to decode that language of chemistry and how it connects to our biology.” “By doing that, it enables us to take advantage of this unbelievably rich and diverse chemistry set that pharma had kind of put to the side,” she said. “It’s how drug development started. It’s a super-proven source of drugs, but it was perceived as complex, hard to make, the challenges with polypharmacology.” Montai was working on a small molecule agonist for an undisclosed pathway in inflammation and immunology when Pfizer realized an antagonist of that pathway could be applied in lung cancer, Georgiadis said. The 65-employee company has created an internal pipeline of nine I&I therapies that are transcription factors and biologic replacements in dermatology, gastrointestinal and respiratory diseases, she said. The company is “developing partnerships” with more companies, Georgiadis said, as Montai’s work applies across immunology, oncology, neuro-inflammation and other areas.

Acquisition

29 Oct 2024

·endpts.com

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

As Pfizer talked up the strength of its pipeline Tuesday, it shared details for the first time about its plans in obesity and said it has a multipronged strategy to catch up to rivals in the field. Danuglipron remains the company’s main bet, CEO Albert Bourla said on the company’s earnings call Tuesday, adding that he believes Pfizer can bring the second oral drug to the market. But that’s not Pfizer’s only option. The company disclosed new details about the mechanism of action behind a second candidate, a GIP antagonist that’s in the same category as other promising pipeline drugs developed by rivals. Amgen, for example, is developing a bispecific molecule named MariTide that’s both a GIP antagonist and GLP-1 agonist. Pfizer’s GIP antagonist is set to enter a Phase 2 study before the end of the year. A once-daily oral GLP-1 is also continuing to progress through a Phase 1 study. Outgoing CSO Mikael Dolsten described the first versions of oral GLP-1s being on the lower end of a range of 10% to 20% reduction in body weight. “The upper range is where you can see oral combinations edge towards,” Dolsten said on Tuesday’s call. And Bourla teased that there could be more, saying Pfizer was “exploring several other opportunities right now.” There is no shortage of smaller obesity biotechs looking for drugmakers to work with — or sell to. Zealand Pharma has been on the hunt for a co-development and commercialization partner for its amylin analog drug, petrelintide . And Rivus Pharmaceuticals CEO Jayson Dallas told Endpoints News last month that he thinks the company’s lead asset, in the middle of two Phase 2 trials, will at some point “pique someone’s interest.” Pfizer’s obesity update may be welcome news for investors who felt the company should have been more aggressive, given its strength in primary care. That includes activist shareholder Starboard Value, which outlined in CEO Jeff Smith’s presentation last week how expectations for danuglipron have fallen since early 2023. “Peers have been successful at developing and commercializing GLP-1s whereas Pfizer has not,” the firm wrote in a presentation to investors this month, arguing that Pfizer’s performance needs to improve or the management needs to be held accountable by the board. Bourla remained encouraged Tuesday, underscoring that if danuglipron can get approved, then Pfizer would have a major product. “The market is very, very large,” Bourla said. “And there is a significant need for oral solutions. We know that. So there is no doubt that if successful, we will have our decent market share of oral.” But the product profile looks “suboptimal” as a once-daily pill, Leerink Partners senior analyst David Risinger said in an interview. “I don’t think that danuglipron is going to be their lead obesity drug in five to 10 years,” he said. Editor’s note: This story was updated to correct the second reference to Pfizer’s GIP antagonist.

Phase 1Phase 2

10 Oct 2024

·www.biopharmadive.com

Drugmakers are racing to find the next Wegovy. These obesity trials are ones to watch.

Within the pharmaceutical industry, a multibillion-dollar race is underway to top Novo Nordisks and Eli Lillys in-demand obesity drugs.Dozens of companies, large and small, have set out to test experimental medicines they claim could be more potent, convenient or have fewer side effects than Novos Wegovy and Lillys Zepbound. But those two companies are already hard at work with successors of their own.The next six months figure to be an important preview. Data are expected for a number of drugs that are already, or are shaping up to be, contenders in this high-stakes competition. The readouts will be closely watched, as they will set expectations for how the obesity drug market currently a duopoly between Lilly and Novo will look in the future. Heres what to expect:Zepbound versus WegovyHead-to-head trials always carry high risk. Any company that sponsors one is doing so with the knowledge testing could reveal its drug is equivalent to a competitor or, worse, less effective.With Zepbound, Eli Lilly appears to believe its a risk worth taking. In a trial called SURMOUNT-5, Lilly enrolled 700 people in an attempt to prove Zepbound is better than Wegovy at reducing the body mass of people with obesity or who are overweight, and have another weight-related complication like heart disease or high blood pressure.It expects to have results by the end of the year, and the findings could impact physician and patient perception of which drug offers greater weight loss benefits..So far, Zepbound has seemed superior, as testing showed treatment helped people with obesity lose up to 21% of their body weight. The comparative figure for Wegovy was 16% in the Phase 3 trials Novo used to gain Food and Drug Administration approval. Based on this, Leerink Partners analyst David Risinger expects Zepbound to show a statistically significant advantage in the head-to-head trial.A resoundingly positive outcome could help push Lilly past $1 trillion in market valuation, a milestone that would be a first among pharmaceutical firms. Lilly is currently worth nearly $900 billion.Yet Lilly has yet to prove Zepbound can prevent cardiovascular complications in people with obesity or who are overweight and already have heart disease, as Novo has with Wegovy. That study result helped Novo gain limited Medicare coverage for people with existing heart disease. Lilly has an outcomes trial called SURPASS-CVOT underway, but doesnt expect to have data until next year.Novos dual agonistWegovy works by stimulating a metabolic hormone called GLP-1, while Zepbound targets GLP-1 and a second one called GIP. The biology behind the dueling approaches is still being sorted, but Zepbounds dual agonism has set a model for others to follow, including Novo.The Danish company is now in late-stage testing with a dual-acting experimental drug it calls cagrisema. The drug combines semaglutide, the active ingredient in Wegovy, with another compound that mimics a metabolic hormone called amylin.Cagrisemas Phase 3 trial, called REDEFINE1, is due to wrap up and generate data in the fourth quarter. The results could help Novo fight off Lillys commercial challenge should SURMOUNT-5 favor Zepbound over Wegovy.REDEFINE1 tests cagrisema against a placebo and Wegovy, measuring weight loss over 68 weeks in about 3,400 people. Cagrisemas performance against Wegovy should give analysts a sense of how well it might also measure up against Zepbound, once the SURMOUNT-5 data are available.Novo is also testing cagrisema directly against Zepbound, but that trial isnt due to generate data for another year.Amgens contenderAmgen isnt known for cardiometabolic drugs, but it has one, called maridebart cafraglutide or maritide, thats among the most closely-watched obesity medicines not owned by either Lilly or Novo.Maritide targets the same two gut hormones, GLP-1 and GIP, that Zepbound does. But, somewhat controversially, it is designed to inhibit rather than stimulate GIP. It is also a monthly shot, compared with the weekly injections used for Wegovy and Zepbound.Phase 2 results for maritide are due by the end of the year. Enthusiasm for the experimental drugs potential has driven Amgens shares higher this year sometimes dramatically so. Phase 1 data Amgen disclosed in February suggested it might drive the most weight loss among tested drugs over 12 weeks, according to Stifel analysts.The Phase 2 trial enrolled nearly 600 people with obesity, some of whom also have diabetes, and randomized them to receive one of several doses of maritide or a placebo. Researchers will measure weight loss over 52 weeks.An obesity pillNovo has advanced an oral version of Wegovy and Lilly has pushed its pill oforgliproninto Phase 3 trials. But there are many rivals staking their competitive future on the idea that people with obesity will prefer a pill over a shot. Roche is one such company, having acquired Carmot Therapeutics for $2.7 billion in late 2023 to gain access to three obesity drugs.A Phase 1 dosing trial of the GLP-1 pill CT-996 is due to wrap up by November, which will give Roche and its investors an idea of the drugs biological activity, safety and weight loss. Roche already reported data from earlier stages of the trial, which tested single and increasing doses in trial volunteers who are overweight or have obesity. The third part will test the pill in 60 people who have diabetes in addition to obesity or being overweight.Roche has already said CT-996 will advance into Phase 2 clinical development based on the Phase 1 data. Its already touting the drugs best-in-class potential, although Phase 2 data will be a better test of that claim. Others are already in Phase 2, including Pfizer with its drug danuglipron and Structure Therapeutics with GSBR-1290. They could soon be joined by Terns Pharmaceuticals TERN-601 and Viking Therapeuticsoral version of VK2735.Preserving muscle massThe rapid weight loss stimulated by GLP-1 agonists melts away muscle as well as fat. That worries some experts, who note how people who discontinue treatment tend to regain weight in the form of fat. Muscle cells also have a higher resting metabolic rate, which results in higher caloric burn.In response, some drugmakers are exploring ways to preserve lean muscle mass. An early test could come in the form of results for Verus enobosarm, a type of drug that stimulates muscle-building hormones. Previously sold under the name Ostarine, it has been tested clinically in people with cancer whose muscles have shrunk, as well as those with muscular dystrophy.In obesity, a Phase 2 test of enobosarm together with Wegovy is underway in people 60 and over who are overweight or have obesity and have lost muscle mass. The trial will measure how much trial volunteers muscle mass changes over 16 weeks, and will compare results in people who receive the two drugs to those who were given only Wegovy. Another endpoint will assess physical function by evaluating how participants climb stairs.Veru expects results by the end of the year. The data could help analysts parse how important lean mass might be in future obesity treatment.A new drug targetOutside of targeting GLP-1, GIP, amylin and other gut hormones, there are a range of other treatment approaches under evaluation. One involves blocking a cannabinoid receptor called CB1 that is known for regulating an appetite-modulating hormone called leptin. CB1 is known to have effects on other biological functions such as inflammation, too.So far, theres been at least one disappointing data point on CB1 inhibition. Phase 2 data for a Novo drug called monlunabant didnt meet expectations for weight loss, leading Novo to state that further work is needed to determine the optimal dosing.The next shot for CB1 may be Skye Biosciences nimacimab, which is due to have interim Phase 2 results by mid-2025. The trial, called CBEYOND, tests nimacimab against placebo, as well as a combination of Wegovy and nimacimab against Wegovy alone. The study will measure weight loss over 26 weeks. Enrolling 120 volunteers, the study should be large enough to detect at least an 8% difference between the experimental drug and placebo, according to the trials plan.Skye shares fell by more than 40% the same day Novo reported its data for monlunabant. '

Phase 2Phase 3AcquisitionPhase 1Clinical Result

100 Deals associated with Danuglipron

External Link

KEGG	Wiki	ATC	Drug Bank
D11910	-	-	DB16043

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Obesity	Phase 2	US	Pfizer Inc.	06 Jan 2021
Diabetes Mellitus, Type 2	Phase 2	US	Pfizer Inc.	15 Oct 2019
Diabetes Mellitus, Type 2	Phase 2	BG	Pfizer Inc.	15 Oct 2019
Diabetes Mellitus, Type 2	Phase 2	CA	Pfizer Inc.	15 Oct 2019
Diabetes Mellitus, Type 2	Phase 2	HU	Pfizer Inc.	15 Oct 2019
Diabetes Mellitus, Type 2	Phase 2	PL	Pfizer Inc.	15 Oct 2019
Diabetes Mellitus, Type 2	Phase 2	SK	Pfizer Inc.	15 Oct 2019
Diabetes Mellitus, Type 2	Phase 2	KR	Pfizer Inc.	15 Oct 2019
Diabetes Mellitus, Type 2	Phase 2	TW	Pfizer Inc.	15 Oct 2019
Liver Injury	Phase 1	US	Pfizer Inc.	30 Dec 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04889157 (CTgov)	Phase 1	Diabetes Mellitus, Type 2	20	Placebo	nlxfstluwx(vdkwthiugl) = qhkryekqyj tmgajmbjzt (snhzqjegas, biaxgmmagx - eeugtqyndk) View more	-	01 Oct 2024
NCT04616027 (CTgov)	Phase 1	Diabetes Mellitus, Type 2	42	PF-06882961 (Healthy and Normal Renal Function)	fupgiyiwkp(knqoomrcfe) = kzepirkizi jnwefqvkyy (ybkkkhztov, ihapkzkqwt - dcunmisbok) View more	-	10 May 2024
				PF-06882961 (T2DM Normal Renal Function)	fupgiyiwkp(knqoomrcfe) = vfejpumplb jnwefqvkyy (ybkkkhztov, umqozfvzqe - artljmdobc) View more
NCT04604496 (CTgov)	Phase 1	Liver Injury	24	PF-06882961 (Without Hepatic Impairment)	mdnwzfpmbt(ugwnfqzihu) = ptmisfymem inckecjemt (udbimzeqpd, zrnkthkalp - ckpdfvbskt) View more	-	21 Mar 2024
				PF-06882961 (Mild Hepatic Impairment)	mdnwzfpmbt(ugwnfqzihu) = hmhfvjuxwn inckecjemt (udbimzeqpd, sbjpfmeqnr - gimopqsdmk) View more
NCT04707313 (Corporate Publications) Manual	Phase 2	Obesity	-	Danuglipron	luxizdjvct(neygrczsle) = jwjfoujnok izyxzrclms (hsrtesjghb ) View more	Negative	01 Dec 2023
				Placebo	luxizdjvct(neygrczsle) = zbyfkscmjx izyxzrclms (hsrtesjghb ) View more
NCT04621227 (CTgov)	Phase 1	Obesity	16	Rosuvastatin (Rosuvastatin 10mg (Period 1))	ehchtxjhoe(nfzslvhbev) = qdznxrrloo karfltmuoz (mzbosmeulo, rwsnoqsyph - zezgyzvrmo) View more	-	01 Dec 2023
				Rosuvastatin+PF-06882961 (PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4))	ehchtxjhoe(nfzslvhbev) = iqlnzcshxa karfltmuoz (mzbosmeulo, vuetikcalq - wfgdvnfcls) View more
NCT04617275 (Pubmed)	Phase 2	Diabetes Mellitus, Type 2	151	Placebo	ltjdpbyqbo(jvphnduvab) = rkbpyhmfde tbbfrkgdsl (rsibxlgpmq ) View more	-	13 Jun 2023
				Danuglipron low starting dose (5-mg)	ltjdpbyqbo(jvphnduvab) = lpxynrxvqs tbbfrkgdsl (rsibxlgpmq ) View more
NCT03985293 (Literature) Manual	Phase 2	Diabetes Mellitus, Type 2	411	Danuglipron 2.5 mg	kvrofeigjf(zfcxgudama) = kqhfxzkcgz lrzhuqlyxw (izgczlfiwy, -0.70 to to 0.28) View more	Positive	22 May 2023
				Danuglipron 10 mg	kvrofeigjf(zfcxgudama) = zqkquwxyeq lrzhuqlyxw (izgczlfiwy, -1.11 to to 0.72) View more
NCT03985293 (Pubmed)	Phase 2	Diabetes Mellitus, Type 2	411	Danuglipron 2.5 mg	cxqugsqdlq(zetygphizo) = cygbvhwnyj cezjmdgnhi (wpfgjrnpyp, -1.47 to -0.86) View more	Positive	01 May 2023
				Danuglipron 80 mg	elbyiwopmc(omezgjozso) = acaycbfzpd mfpslhrnye (hggxqogjxw, -3.01 to -1.07)
NCT04617275 (CTgov)	Phase 2	Diabetes Mellitus, Type 2 \| Obesity	151	Placebo (Placebo (T2DM))	jzwwojassy(qbjwtuccfc) = siclytceec ikuyqswjix (yhzzdysuck, lflifzoeza - lekmzdjzei) View more	-	08 Dec 2022
				PF-06882961 (PF-06882961 80 mg BID Low, Slow (T2DM))	jzwwojassy(qbjwtuccfc) = ylwaxbgjtw ikuyqswjix (yhzzdysuck, nqbbtwubqm - zjcaacbfmy) View more
NCT04552470 (Pubmed) Manual	Phase 1	Diabetes Mellitus, Type 2	37	danuglipron	bllrynsaim(yufxbwcuan) = Most treatment-emergent adverse events were of mild or moderate intensity. kmubttamcg (yljqtiexql )	Positive	26 Nov 2022
				Placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis